Seigo Kashii

StemCyte, Inc. operates as a biotechnology company that collects, banks and distributes cord blood stem cell transfusion units. It focuses on stem cell transplantation, therapy, applications, diagnostics, and genomic research. The firm uses insulated containers to keep your baby's cord blood cool throughout transport. The company was founded by Denis Rodgerson and Robert Chow in 1997 and is headquartered in Covina, CA.

NeoStem Oncology LLC is focused on the production and supply of clinically relevant embryonic stem cell derived human cell populations. Founded in 2005, the mission of NeoStem Oncology is to catalyze the efficient development of human therapies based on human embryonic stem cells. The key to this goal is the production and supply of clinically relevant human cell populations using a scalable, efficient and highly reproducible process. They generate human embryonic stem cell (hESC) lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes that are FDA compliant from day one. And they do this at a fraction of the cost of conventional cell manufacturing. As a result, the company can economically supply large quantities of high purity cells for its own clinical development pipeline in specific application areas. It can also supply high purity, fully characterized, clinically relevant human cell populations to companies or other institutions for development of therapies, efficacy screening or creation of toxicity profiles for candidate drugs, or experimental research. NeoStem Oncology LLC is a privately held Delaware Corporation with headquarters and research facilities in Irvine, CA.

Mesa Verde Ventures LLC (Mesa Verde Ventures) is a venture capital firm founded in 2006. The firm is headquartered in San Diego, California.

Kalyra Pharmaceuticals, Inc. manufactures small molecule drugs. The company was founded by Brian T. Dorsey, Cam L. Garner and Kevin Bunker and is headquartered in San Diego, CA.

Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Part of Deloitte LLP (New York), Tohmatsu Corp. is a Japanese company that provides accounting services. The company is based in Tokyo, Japan.

International Society for Cellular Therapy conducts research, processing, and manipulation of cells. The private company is based in Vancouver, CA. The Canadian company publishes researched materials. and has subsidiaries in the United States.

Aqumen Biopharmaceuticals KK is a holding company that provides research and development of therapeutic medicines for macular degeneration. It also develops therapeutics for diabetic retinopathy, diabetic nephropathy, adjuvants for ophthalmic surgery, and intraocular drug delivery systems. The firm's products encompass the ILM-Blue and the MembraneBlue-Dual. The company was founded by Kimihiko Fujisawa and Tadahisa Kagimoto on April 11, 2005 and is headquartered in Fukuoka, Japan.

Nezu Asia Capital Management Ltd. (Nezu HK) is the alternative investment management subsidiary of Nezu Group S.A.R.L., itself owned by Nezu Group LP in the US. Headquartered in Hong Kong, Nezu HK was founded in 2004 and they provide discretionary investment advisory services to separately managed accounts and a private investment fund, which is open only to certain financially sophisticated and high-net worth individuals and entities.

selectION, Inc. provides a technology platform to develop peptide blockers for ion channels. The company was founded by Andreas Klostermann and is headquartered in San Diego, CA.

Uruma Law Offices Legal Professional Corp provides legal services. The private company is based in Tokyo, Japan.

Nezu Asia Capital Management (Singapore) Pte Ltd. (Nezu Asia SG) is an independent hedge fund manager headquartered in Singapore. Nezu Asia SG manages long/short equity portfolios.

Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada.

Insitut de Recherche en Immunologie et en Cancérologie develops and discovers treatment and therapies for cancers. It also engages in anticancer drug discovery chain. The company was founded in 2003 and is headquartered in Montréal, Canada.

FiNC inc. operates as a provider of an online diet coach service. It specializes in deoxyribonucleic acid (DNA) analysis and environment inspection; and utilizes these data to create customized diet programs. The firm also operates fitness gyms, and provides online diet tutoring. It develops and operates an application that allows users to access diet programs and trainings created by the firm. The company was founded by Yuji Mizoguchi on April 11, 2012 and is headquartered in Tokyo, Japan.

Nezu Master Strategy Feeder Ltd. Operates as a private equity fund. The company is headquartered in Grand Cayman, Cayman Islands.

Muuseo, Inc. operates museums. The private company is based in Tokyo, Japan.

Oncternal Oncology, Inc. is a clinical-stage oncology company, which engages in the development of novel therapies for both rare and common cancers. The company was founded by Lauren Otsuki and Cam L. Garner and is headquartered in San Diego, CA.

Unitedly Co., Ltd. is a private company based in Japan that aims to accelerate business succession throughout the country. The Japanese company does this by utilizing financial technology to ensure the correct distribution of mergers and acquisitions information. The company's ultimate goal is to contribute to the Japanese economy.

OcuSub, Inc. engages biotechnology services. It specializes in eye disorder treatment. The company was founded by Mina Patel Sooch, Alan R. Meyer, and William H. Pitlick in 2018 and is headquartered in Farmington Hills, MI.

jCyte, Inc. engages in the provision of retinal therapies. Its therapy focuses with retinitis pigmentosa, and retinal progenitor cells. The company was founded by Terry O?Neal, Henry Klassen and Jing Yang in 2012 and is headquartered in Newport Beach, CA.

Saisei Ventures LLC (Saisei Ventures) is a venture capital firm founded by Jonathan Yeh in 2020. The firm is headquartered in Cambridge, Massachusetts.

Ray Therapeutics, Inc. is an American company that is developing a lead candidate, RTX-015, to treat retinitis pigmentosa, a degenerative retinal disease. Ray Therapeutics is based in an undisclosed location. The company's mission is to restore vision for people with retinal degeneration using optogenetics gene therapies. Ray Therapeutics is pursuing multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company was founded by Paul Bresge and Sean Ainsworth, with Paul Bresge serving as CEO since incorporation.

PowerX, Inc. is a Japanese next-generation energy company that aims to build a new energy grid of renewable energy storage. The company is based in Minato-ku, Japan, and the CEO of the company is Masahiro Ito. The company will construct a large-scale storage battery factory to manufacture and sell battery products that realize the explosive spread of natural energy. The PowerX ship battery is a safe and secure product that uses LFP, which is a safe and long-life battery. The battery can be installed in racks and provided as a large-capacity type of the industry-standard 10 or 20ft container type. With PowerX's large industrial storage battery mega power, businesses can significantly reduce their electricity bills. The company's solution can be introduced right now and will be available for shipping from 2023.

Ryne Biotechnology, Inc. is an American US-based biotechnology company that focuses on developing next-generation approaches to cure neurological disorders. The company utilizes induced pluripotent stem cell (iPSC) technology to advance its off-the-shelf neuron replacement therapeutics. Ryne Bio is dedicated to advancing a pipeline targeting neurological diseases by focusing on an iPSC technology platform and forging partnerships with leaders in surgical delivery and clinical development.